Elixir Pharmaceuticals Inc. is now initiating a phase 3 clinical trial of their drug for type 2 diabetics, according to official reports from the company.
The new diabetes drug, known as mitiglinide, is set to help diabetics throughout the UK control their blood sugar levels, not to mention assisting them in producing the insulin needed to operate.
Officials in the company, which is based in Cambridge and has strong biotechnological capability, are aiming for Food and Drug Administration approval during 2009.
The phase three study, an advanced level of blood testing, involves 300 participants throughout 50 sites in America. The trial will conclude during 2008, following venture capital backing.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…